<DOC>
	<DOCNO>NCT00068575</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin fluorouracil , use different way stop tumor cell divide stop grow die . Biological therapy interferon alfa may interfere growth tumor cell slow growth cancer . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy interferon alfa radiation therapy surgery may kill remain tumor cell . PURPOSE : This phase II trial study well give cisplatin , fluorouracil , interferon alfa together radiation therapy work treat patient undergone surgery stage I , stage II , stage III pancreatic cancer .</brief_summary>
	<brief_title>Chemotherapy , Interferon Alfa , Radiation Therapy Treating Patients Who Have Undergone Surgery For Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall survival patient previously resect pancreatic adenocarcinoma treat postoperative cisplatin , interferon alfa , fluorouracil , concurrent radiotherapy . - Determine toxic effect regimen patient . Secondary - Determine disease-specific , biochemical failure-free , symptom/treatment-free survival patient treat regimen . - Determine quality life patient treat regimen . OUTLINE : - Chemoradiotherapy : Patients receive fluorouracil intravenous ( IV ) continuously interferon alfa subcutaneously ( SQ ) 3 time per week ( total 17 dos ) day 1-19 29-45 cisplatin IV 6 hour day 1 , 8 , 15 , 29 , 36 43 . Patients also undergo concurrent radiotherapy daily , 5 day week week 1-3 5-7 ( 28 fraction ) . - Post-chemoradiotherapy fluorouracil : Patients receive fluorouracil IV continuously day 71-108 127-168 . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Biopsy proven completely resect ( R0 R1 ) pancreatic adenocarcinoma pancreatic head uncinate process [ American Joint Committee Cancer ( AJCC ) Stage IIII ] . Surgery ( pancreaticoduodenectomy ) may perform M. D. Anderson Cancer Center prior referral M. D. Anderson Cancer Center . Protocol treatment must begin within 12 week surgery . 2 . Postoperative ( pretreatment ) compute tomography ( CT ) scan without evidence radiographically defineable residual primary/metastatic disease clinically significant postsurgical change . 3 . Staging study complete within three week +/ 3 day protocol registration . 4 . Hemoglobin ( Hb ) &gt; 9.0 g/ % , White Blood Count ( WBC ) &gt; 3,000 cells/mm3 ( Absolute neutrophil count ( ANC ) &gt; 1,500 cells/mm3 ) , platelets &gt; 75,000 cells/mm3 . 5 . Postoperative serum calcium ( CA ) 199 &lt; 100 . 6 . Performance status : Zubrod 0 1 . 7 . Creatinine £1.5 mg/dL calculate measured creatinine clearance ( CrCl ) 60 ml/min great follow formula : Creatinine clearance rate ( CrCl ) = ( 140 age ) * Weight ( kg ) * 0.85 ( female ) OR * 1.00 ( male ) 72 * serum creatinine 8 . Patients bilateral renal function , determine excretory urogram ( IVP ) abdominal CT , ³ 2/3 one functioning kidney must able shield radiation beam . 9 . No acute infection time therapy initiation . 10 . Women childbearing potential must agree practice adequate contraception refrain breast feeding , specify informed consent . 11 . Patients must sign studyspecific consent form , attach protocol . 12 . Patients prior history nonpancreatic malignancy free disease primary cancer may eligible discretion study chair . 1 . Residual ( clinical CT definable ) metastatic incompletely resect local disease . 2 . Patients positive peritoneal cytology ( adenocarcinoma ) detect laparotomy pancreaticoduodenectomy part prior laparoscopic assessment peritoneal cytology . 3 . Patients history hypersensitivity interferon alfa2b . 4 . Patients significant cardiovascular disease , unstable angina congestive heart failure . 5 . Pregnancy breastfeed . 6 . Patients severe pulmonary disease . 7 . Children age 18 exclude ( disease rare toxicity profile regimen untested pediatric patient ) . 8 . Presence history severe depression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>